KATHMANDU: The World Health Organization (WHO) has decided to recommence the clinical trials of hydroxychloroquine (HCQ), an anti-malaria drug, which had been halted citing safety concerns, for the treatment of coronavirus infection.

"Based on available data, the COVID-19 Solidarity Trial Data Safety and Monitoring Committee recommended there are no reasons to modify the trial protocol. The Executive Group endorsed the continuation of all arms of the Trial, including the use of hydroxychloroquine," stated WHO Director-General Tedros Adhanom Ghebreyesus, on Wednesday.

Based on available data, the #COVID19 Solidarity Trial Data Safety & Monitoring Committee recommended there are no reasons to modify the trial protocol. The Executive Group endorsed the continuation of all arms of the Trial, including the use of hydroxychloroquine. https://t.co/r88DVEvZ3j pic.twitter.com/cYITShxcE7

— Tedros Adhanom Ghebreyesus (@DrTedros) June 3, 2020